Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Type of Breast Reconstruction Impacts Radiation Therapy Outcomes - (DGNews)
    Study Identifies Causes of Bone Loss in Breast Cancer Survivors - (DGNews)
    TopAbstracts in Breast Cancer 11/18/2008 - (DGNews)
    Psychological Interventions Associated With Breast Cancer Survival - (DGNews)
    Aromatase Inhibitors, Androgen Deprivation Increase Risk of Bone Loss - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
      Granular Cell Tumour of the Pectoral Muscle Mimicking Breast Cancer
      Primary Osteosarcoma of the Breast: Case Report
      A Case of Matrix-Producing Carcinoma of the Breast
      Metastatic Hurthle Cell Carcinoma of the Thyroid Presenting as a Breast Lump: A Case Report

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Taxotere and Cyclophosphamide Appears to Improve Disease-Free Survival in Patients With Operable Breast Cancer: Presented at CFS

      By Charlene Laino

      NEW YORK, NY -- November 19, 2003 -- In patients with Stage I-III operable invasive breast cancer, a trend toward longer disease-free survival was observed with taxotere and cyclophosphamide, compared with doxorubicin and cyclophosphamide, a prospective randomised controlled trials shows.

      "At 3 years, there was a 21% reduction in the risk of recurrence in patients given taxotere and cyclophosphamide," said Stephen Jones, E. MD, Chair, US Oncology Breast Cancer Research, Houston, Texas, Untied States. Dr. Jones presented the findings here on November 13th at Chemotherapy Foundation Symposium XXI.

      The trial included 1,016 patients who were randomised to receive either 4 courses of the standard dose of doxorubicin and cyclophosphamide, 60/600 mg/m2, or four courses of taxotere and cyclophosphamide, 75/600 mg/m2, each given every 3 weeks preceding adjuvant radiation therapy and tamoxifen if indicated.

      At a median follow-up of 46 months, 9% patients in the taxotere and cyclophosphamide arm had relapsed, compared to 12% of patients given doxorubicin and cyclophosphamide. Also, mortality was 7.5% in patients given taxotere and cyclophosphamide, compared to 9% for those on doxorubicin and cyclophosphamide, the study showed.

      "There were no significant differences in disease-free survival although a trend in favour of taxotere and cyclophosphamide over doxorubicin and cyclophosphamide in terms of disease-free survival was noted [P = .13]," Dr. Jones said.

      "Longer follow-up is needed to determine whether taxotere and cyclophosphamide is more effective than doxorubicin and cyclophosphamide in the adjuvant setting," he added.

      The study is exciting, he said, because it suggests that the non-anthracycline-based regimen of taxotere and cyclophosphamide is at least equivalent and possibly superior to the standard adjuvant regimen of doxorubicin and cyclophosphamide, he said.

      "Taxotere and cyclophosphamide should be considered as an adjuvant regimen in special circumstances, such as prior [to] anthracycline use and [in patients with] cardiac disease," he said.


      [Study title: Results of a Prospective Randomized Trial of Adjuvant Chemotherapy for Patients with Stage I-III Operable, Invasive Breast Cancer, Comparing 4 Courses of Adriamycin/Cyclophosphamide to 4 Courses of Taxotere/Cyclophosphamide. Abstract 26]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send